Protagonist Therapeutics Inc (PTGX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Dinesh V. Patel
Employees:
120
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA 94560-1160
(510) 474-0170

Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.

Data derived from most recent annual or quarterly report
Market Cap 1.171 Billion Shares Outstanding57.53 Million Avg 30-day Volume 583.862 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.64
Price to Revenue0.0 Debt to Equity0.0 EBITDA-154.206 Million
Price to Book Value3.2672 Operating Margin0.0 Enterprise Value664.435 Million
Current Ratio11.658 EPS Growth0.026 Quick Ratio11.51
1 Yr BETA 0.519 52-week High/Low 30.1 / 7.45 Profit Margin0.0
Operating Cash Flow Growth-14.878 Free Cash Flow to Firm (FCFF) TTM -110.486 Million Free Cash Flow to Equity (FCFE) TTM
Altman Z-Score18.0728
View SEC Filings from PTGX instead.

View recent insider trading info

Protagonist Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding PTGX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PTGX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-10-23 by GUPTA SUNEEL
  • 4: filed on 2023-06-02 by GUPTA SUNEEL
  • 4: filed on 2023-06-02 by ALI ASIF
  • 4: filed on 2023-04-19 by ALI ASIF
  • 4: filed on 2023-04-11 by SELICK HAROLD E
  • 4: filed on 2023-01-18 by GUPTA SUNEEL
  • 4: filed on 2023-01-18 by ALI ASIF
  • 4: filed on 2023-01-18 by MOLINA ARTURO MD
  • 4: filed on 2023-01-18 by PATEL DINESH V PH D
  • 4: filed on 2022-11-17 by LIU DAVID Y

    • Events (8k)

  • 8-K: filed on 2023-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-05:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-03:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-05-30:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    26 Thousand total shares from 2 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SWISHER DANIEL N JR

    • Director
    		 0 2023-10-26 2

    GUPTA SUNEEL CHIEF DEVELOPMENT OFFICER

    • Officer
    		 168,317 2023-10-19 3

    PATEL DINESH V PH D PRESIDENT AND CEO

    • Officer
    • Director
    		 609,347 2023-10-18 3

    ALI ASIF CHIEF FINANCIAL OFFICER

    • Officer
    		 31,036 2023-05-31 3

    SELICK HAROLD E

    • Director
    		 21,506 2023-04-10 2

    MOLINA ARTURO MD CHIEF MEDICAL OFFICER

    • Officer
    		 43,125 2023-01-16 1

    O'DOWD SARAH A

    • Director
    		 30,000 2023-01-16 1

    WILLIAMS LEWIS T

    • Director
    		 30,000 2023-01-16 1

    WADDILL WILLIAM D.

    • Director
    		 30,000 2023-01-16 1

    NOONBERG SARAH B.

    • Director
    		 30,000 2023-01-16 1

    GIRAUDO BRYAN

    • Director
    		 30,000 2023-01-16 1

    LIU DAVID Y CHIEF R&D STRATEGY OFFICER

    • Officer
    		 167,590 2022-11-16 0

    KALKOFEN DONALD A. CHIEF FINANCIAL OFFICER

    • Officer
    		 63,521 2022-02-15 0

    SAKS SAMUEL R CHIEF MEDICAL OFFICER

    • Officer
    		 104,000 2021-02-26 0

    KHOSLA CHAITAN PHD

    • Director
    		 0 2020-08-11 0

    SHAMES RICHARD S. CHIEF MEDICAL OFFICER

    • Officer
    		 32,021 2019-02-28 0

    MURPHY NIALL VP, CONTROLLER, INTERIM PAO

    • Officer
    		 0 2019-01-11 0

    O'NEIL THOMAS P. CHIEF FINANCIAL OFFICER

    • Officer
    		 30,560 2018-08-15 0

    SHANAFELT ARMEN

    • Director
    • 10% Owner
    		 0 2018-05-29 0

    CANAAN X L.P.

    CANAAN PARTNERS X LLC

    • 10% Owner
    		 No longer subject to file 2018-05-17 0

    ADAGE CAPITAL PARTNERS GP, L.L.C.

    ADAGE CAPITAL PARTNERS, L.P.

    ADAGE CAPITAL ADVISORS, L.L.C.

    ATCHINSON ROBERT

    GROSS PHILLIP

    • 10% Owner
    		 No longer subject to file 2017-12-31 0

    PAPANEK JULIE

    • Director
    		 0 2017-05-25 0

    HODDER WILLIAM A SR. VP - CORPORATE DEVELOPMENT

    • Officer
    		 0 2016-10-11 0

    JOHNSON & JOHNSON

    JOHNSON & JOHNSON INNOVATION - JJDC, INC.

    • 10% Owner
    		 2,449,183 2016-08-16 0

    LV MANAGEMENT GROUP, LLC

    LILLY VENTURES FUND I LLC

    TORRES S. EDWARD

    HALL STEVEN EDWARD

    • 10% Owner
    		 2,099,482 2016-08-16 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SWISHER DANIEL N JR - Director

    		2023-10-30 16:31:33 -0400 2023-10-26 A 45,000 a 45,000 direct

    GUPTA SUNEEL - Officer CHIEF DEVELOPMENT OFFICER

    		2023-10-23 16:31:12 -0400 2023-10-19 M 20,000 $7.38 a 168,317 direct -1.1228 2.0351 47.0175 47.0175 31 -1.193 4

    GUPTA SUNEEL - Officer CHIEF DEVELOPMENT OFFICER

    		2023-10-23 16:31:12 -0400 2023-10-19 M 20,000 d 50,000 direct

    PATEL DINESH V PH D - Director - Officer PRESIDENT AND CEO

    		2023-10-19 16:55:30 -0400 2023-10-18 M 6,000 $4.21 a 609,347 direct -2.5659 -2.3578 26.491 28.7101 30 -2.5659 2

    PATEL DINESH V PH D - Director - Officer PRESIDENT AND CEO

    		2023-10-19 16:55:30 -0400 2023-10-18 M 6,000 d 54,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 22:15:04 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 21:45:04 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 21:15:04 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 20:45:04 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 20:15:07 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 19:45:04 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 19:15:03 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 18:45:03 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 18:15:04 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 17:45:03 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 17:15:03 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 16:45:05 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 16:15:04 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 15:45:04 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 15:15:04 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 14:45:04 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 14:15:03 UTC 4.79 0.53 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 13:45:03 UTC 4.6073 0.7127 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 13:15:04 UTC 4.6073 0.7127 950000
    PROTAGONIST THERAPEUTICS INC PTGX 2023-12-08 12:45:05 UTC 4.6073 0.7127 950000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund PTGX -90.0 shares, $-1080.9 2019-09-30 N-PORT
    Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio PTGX -3700.0 shares, $-65564.0 2021-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments